A naukri.com initiative
SiliconCanals
1M
393
Image Credit: SiliconCanals
Wageningen-based Scope Biosciences lands fresh capital to advance CRISPR-based molecular diagnostics platform
- Wageningen-based Scope Biosciences secures follow-on investment from SHIFT Invest and Oost NL to advance its CRISPR-based molecular diagnostics platform.
- The company, founded by CEO Niek Savelkoul and headquartered in Wageningen, has raised a total of €6M in seed-stage funding along with support from European and Dutch innovation programs.
- Scope Biosciences' scopeDx technology enables ultra-precise, field-ready diagnostics without proprietary hardware, targeting agricultural and healthcare markets.
- The platform offers single-nucleotide detection in a portable format, aiding in earlier crop disease detection and improving healthcare testing accessibility.
- The company has received continued backing from existing investors SHIFT Invest and Oost NL, combining public and private funding to scale up its operations.
- The technology developed by Scope Biosciences originated as a spin-off from Wageningen University & Research, focused on molecular diagnostics.
- SHIFT Invest and Oost NL bring sector-specific and regional innovation expertise, respectively, to support the company's growth.
- Scope Biosciences aims to bring its technology closer to market with the additional funding secured for real-world diagnostic challenges.
- The company's innovative diagnostic platform is driving growth in the molecular diagnostics market, meeting the demand for point-of-care testing solutions.
- Scope Biosciences operates from the Wageningen Campus within the East Netherlands region, showcasing commercial success in agricultural diagnostics and expanding into healthcare applications.
- The company's efforts align with the regional innovation hub's goal to support global diagnostic solutions.
- CEO Niek Savelkoul expresses gratitude for continued support and highlights the company's commitment to scaling up and addressing diagnostic challenges.
- Associate at SHIFT Invest, Sophie van Weede, commends ScopeBio's progress in commercializing accurate diagnostic platforms and expanding into healthcare.
- Investment Manager at Oost NL, Maureen Haverkamp, expresses pride in supporting ScopeBio's growth and innovation in regional and global contexts.
- Scope Biosciences' technology offers promising solutions for agriculture and healthcare markets, leveraging CRISPR-based molecular diagnostics for effective testing.
- The company's success reflects its ability to provide on-site, precise diagnostics without the need for central laboratories, supporting faster and efficient testing processes.
Read Full Article
23 Likes
For uninterrupted reading, download the app